{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:44:08Z","timestamp":1790462648952,"version":"4.1.0"},"reference-count":75,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81822045"],"award-info":[{"award-number":["81822045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81630090"],"award-info":[{"award-number":["81630090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703571"],"award-info":[{"award-number":["81703571"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018536","name":"National Megaprojects of China for Major Infectious Diseases","doi-asserted-by":"publisher","award":["2018ZX10301403"],"award-info":[{"award-number":["2018ZX10301403"]}],"id":[{"id":"10.13039\/501100018536","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In the past 17 years, three novel coronaviruses have caused severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and the coronavirus disease 2019 (COVID-19). As emerging infectious diseases, they were characterized by their novel pathogens and transmissibility without available clinical drugs or vaccines. This is especially true for the newly identified COVID-19 caused by SARS coronavirus 2 (SARS-CoV-2) for which, to date, no specific antiviral drugs or vaccines have been approved. Similar to SARS and MERS, the lag time in the development of therapeutics is likely to take months to years. These facts call for the development of broad-spectrum anti-coronavirus drugs targeting a conserved target site. This review will systematically describe potential broad-spectrum coronavirus fusion inhibitors, including antibodies, protease inhibitors, and peptide fusion inhibitors, along with a discussion of their advantages and disadvantages.<\/jats:p>","DOI":"10.3390\/ijms21113843","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T10:02:45Z","timestamp":1590660165000},"page":"3843","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1229-4152","authenticated-orcid":false,"given":"Xinling","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-4182","authenticated-orcid":false,"given":"Shuai","family":"Xia","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Reproduction Regulation of National Health Commission, (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2255-0391","authenticated-orcid":false,"given":"Lu","family":"Lu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-7135","authenticated-orcid":false,"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Medical Molecular Virology (MOE\/NHC\/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai 200032, China"},{"name":"Key Laboratory of Reproduction Regulation of National Health Commission, (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"ref_1","unstructured":"(2020, April 26). Coronavirus Disease (COVID-19) Pandemic. Available online: https:\/\/www.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)30419-0","article-title":"A distinct name is needed for the new coronavirus","volume":"395","author":"Jiang","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol., 5, 536\u2013544.","DOI":"10.1038\/s41564-020-0695-z"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/22221751.2020.1723441","article-title":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: Calling for developing therapeutic and prophylactic strategies","volume":"9","author":"Jiang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_5","unstructured":"(2020, April 26). Prioritizing Diseases for Research and Development in Emergency Contexts. Available online: https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Jiang, S., and Shi, Z. (2020). The First Disease X Is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus. Virol. Sin.","DOI":"10.1007\/s12250-020-00206-5"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: Recent insights into emerging coronaviruses","volume":"14","author":"Falzarano","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_8","unstructured":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (2020, April 26). MERS Monthly Summary, November 2019. Available online: https:\/\/www.who.int\/emergencies\/mers-cov\/en\/."},{"key":"ref_9","unstructured":"Coronavirus Disease (COVID-19) Pandemic (2020, April 26). Coronavirus Disease (COVID-19) Outbreak Situation. Available online: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/CMR.00023-07","article-title":"Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection","volume":"20","author":"Cheng","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104792","DOI":"10.1016\/j.antiviral.2020.104792","article-title":"Coronavirus membrane fusion mechanism offers a potential target for antiviral development","volume":"178","author":"Tang","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1126\/science.1058613","article-title":"Evolution of cell recognition by viruses","volume":"292","author":"Baranowski","year":"2001","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bourgonje, A.R., Abdulle, A.E., Timens, W., Hillebrands, J.L., Navis, G.J., Gordijn, S.J., Bolling, M.C., Dijkstra, G., Voors, A.A., and Osterhaus, A. (2020). Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19). J. Pathol.","DOI":"10.1002\/path.5471"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"19970","DOI":"10.1073\/pnas.0908837106","article-title":"Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor","volume":"106","author":"Wu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/357420a0","article-title":"Human Aminopeptidase-N Is a Receptor for Human Coronavirus-229E","volume":"357","author":"Yeager","year":"1992","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.antiviral.2013.08.014","article-title":"Receptor recognition and cross-species infections of SARS coronavirus","volume":"100","author":"Li","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1128\/JVI.06882-11","article-title":"Evidence for a Common Evolutionary Origin of Coronavirus Spike Protein Receptor-Binding Subunits","volume":"86","author":"Li","year":"2012","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Liu, Z., Xia, S., Wang, X., Lan, Q., Xu, W., Wang, Q., Jiang, S., and Lu, L. (2020). Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virol. Sin.","DOI":"10.1007\/s12250-020-00214-5"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1128\/JVI.00433-14","article-title":"A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein","volume":"88","author":"Du","year":"2014","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.4049\/jimmunol.174.8.4908","article-title":"Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies","volume":"174","author":"He","year":"2005","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1073\/pnas.0307140101","article-title":"Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association","volume":"101","author":"Sui","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014A target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/tra.12389","article-title":"Fusion of Enveloped Viruses in Endosomes","volume":"17","author":"White","year":"2016","journal-title":"Traffic"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.1128\/JVI.00079-09","article-title":"Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion Peptide","volume":"83","author":"Madu","year":"2009","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15214","DOI":"10.1073\/pnas.1407087111","article-title":"Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein","volume":"111","author":"Millet","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nature12711","article-title":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor","volume":"503","author":"Ge","year":"2013","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1073\/pnas.1517719113","article-title":"SARS-like WIV1-CoV poised for human emergence","volume":"113","author":"Menachery","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Earnest, J.T., Hantak, M.P., Li, K., McCray, P.B., Perlman, S., and Gallagher, T. (2017). The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006546"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","article-title":"Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors","volume":"363","author":"Liu","year":"2004","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Xia, S., Zhu, Y., Liu, M., Lan, Q., Xu, W., Wu, Y., Ying, T., Liu, S., Shi, Z., and Jiang, S. (2020). Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol. Immunol.","DOI":"10.1038\/s41423-020-0374-2"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14728222.2017.1271415","article-title":"MERS-CoV spike protein: A key target for antivirals","volume":"21","author":"Du","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","article-title":"Structure-based discovery of a novel angiotensin converting enzyme 2 inhibitor","volume":"44","author":"Huentelman","year":"2004","journal-title":"Hypertension"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Xia, S., Xu, W., Wang, Q., Wang, C., Hua, C., Li, W., Lu, L., and Jiang, S. (2018). Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. Int. J. Mol. Sci, 19.","DOI":"10.3390\/ijms19020487"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1073\/pnas.0701000104","article-title":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies","volume":"104","author":"Zhu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1128\/JVI.02377-07","article-title":"Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge","volume":"82","author":"Rockx","year":"2008","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.00912-14","article-title":"Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies","volume":"88","author":"Ying","year":"2014","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Yang, Y., Huang, J., Jiang, S., and Du, L. (2019). Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses, 11.","DOI":"10.3390\/v11010060"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., and Li, Z. (2020). Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol. Immunol.","DOI":"10.1101\/2020.04.06.20055475"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wang, C., Li, W., Drabek, D., Okba, N.M., van Haperen, R., Osterhaus, A.D., van Kuppeveld, F.J., Haagmans, B.L., Grosveld, F., and Bosch, B.J. (2020). A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun.","DOI":"10.1101\/2020.03.11.987958"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., and Du, L. (2020). Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol. Immunol.","DOI":"10.1038\/s41423-020-0400-4"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Magrone, T., Magrone, M., and Jirillo, E. (2020). Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target\u2014A Perspective. Endocr. Metab. Immune Disord. Drug Targets.","DOI":"10.2174\/1871530320666200427112902"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.3390\/v6093683","article-title":"IFITM Proteins Inhibit Entry Driven by the MERS-Coronavirus Spike Protein: Evidence for Cholesterol-Independent Mechanisms","volume":"6","author":"Wrensch","year":"2014","journal-title":"Viruses-Basel"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"22008","DOI":"10.1038\/srep22008","article-title":"A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"12552","DOI":"10.1128\/JVI.01890-13","article-title":"Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2","volume":"87","author":"Shirato","year":"2013","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hoffmann, M., Schroeder, S., Kleine-Weber, H., Muller, M.A., Drosten, C., and Pohlmann, S. (2020). Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.00754-20"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.188.4.725","article-title":"Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection","volume":"188","author":"Engel","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome\/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_66","unstructured":"Zhang, J., Ma, X., Yu, F., Liu, J., Zou, F., Pan, T., and Zhang, H. (2020). Teicoplanin potently blocks the cell entry of 2019-nCoV. BioRxiv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"Hiv-1 Inhibition by a Peptide","volume":"365","author":"Jiang","year":"1993","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"34045","DOI":"10.1074\/jbc.M805536200","article-title":"Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor: Equipotent to C34 and T-20 in Vitro With Sustained Activity in SCID-hu Thy\/Liv Mice","volume":"283","author":"Stoddart","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"25506","DOI":"10.1074\/jbc.M110.101170","article-title":"Novel Recombinant Engineered gp41 N-terminal Heptad Repeat Trimers and Their Potential as Anti-HIV-1 Therapeutics or Microbicides","volume":"285","author":"Chen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e02002","DOI":"10.1128\/JVI.02002-17","article-title":"Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape","volume":"92","author":"Wang","year":"2018","journal-title":"J. Virol."},{"key":"ref_71","first-page":"21","article-title":"Acute eosinophilic pneumonia caused by camostat mesilate: The first case report","volume":"19","author":"Ota","year":"2016","journal-title":"Respir. Med. Case Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1067\/msy.2001.115827","article-title":"Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis","volume":"130","author":"Keck","year":"2001","journal-title":"Surgery"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: Current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1517\/13543784.11.12.1837","article-title":"Enfuvirtide","volume":"11","author":"Chen","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Su, S., Rasquinha, G., Du, L., Wang, Q., Xu, W., Li, W., Lu, L., and Jiang, S. (2019). A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. Molecules, 24.","DOI":"10.3390\/molecules24061134"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/3843\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:33:31Z","timestamp":1760175211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/3843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":75,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ijms21113843"],"URL":"https:\/\/doi.org\/10.3390\/ijms21113843","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]}}}